CR20150642A - Preparado farmaceutico - Google Patents

Preparado farmaceutico

Info

Publication number
CR20150642A
CR20150642A CR20150642A CR20150642A CR20150642A CR 20150642 A CR20150642 A CR 20150642A CR 20150642 A CR20150642 A CR 20150642A CR 20150642 A CR20150642 A CR 20150642A CR 20150642 A CR20150642 A CR 20150642A
Authority
CR
Costa Rica
Prior art keywords
solution
child
pharmaceutical preparation
alpha emitting
selective binder
Prior art date
Application number
CR20150642A
Other languages
English (en)
Inventor
Janne Olsen Frenvik
Olav B Ryan
Alan Cuthbertson
Original Assignee
Bayer As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer As filed Critical Bayer As
Publication of CR20150642A publication Critical patent/CR20150642A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Saccharide Compounds (AREA)

Abstract

Un método para generar una solución purificada de por lo menos un complejo de radionúclido emisor alfa. El método comprende poner en contacto una solución del complejo de radionúclido emisor alfa y por lo menos un núclido hijo que tiene por lo menos un ligante selectivo para los núclidos hijos y subsiguientemente separar la solución del ligante selectivo. También, un método para separar por lo menos un radionúclido hijo de una solución que comprende por lo menos un complejo de radionúclido emisor alfa. El método comprende poner en contacto la solución que tiene por lo menos un ligante selectivo para los núclidos hijos.
CR20150642A 2013-06-05 2015-12-04 Preparado farmaceutico CR20150642A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1310028.4A GB201310028D0 (en) 2013-06-05 2013-06-05 Pharmaceutical preparation
PCT/EP2014/061743 WO2014195423A1 (en) 2013-06-05 2014-06-05 Pharmaceutical preparation

Publications (1)

Publication Number Publication Date
CR20150642A true CR20150642A (es) 2016-07-22

Family

ID=48805787

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150642A CR20150642A (es) 2013-06-05 2015-12-04 Preparado farmaceutico

Country Status (36)

Country Link
US (2) US20160114063A1 (es)
EP (1) EP3003401B1 (es)
JP (1) JP6580559B2 (es)
KR (1) KR102321763B1 (es)
CN (1) CN105592863B (es)
AP (1) AP2015008894A0 (es)
AU (1) AU2014276885B2 (es)
BR (1) BR112015030298A2 (es)
CA (1) CA2914278C (es)
CL (1) CL2015003554A1 (es)
CR (1) CR20150642A (es)
CU (1) CU24535B1 (es)
DK (1) DK3003401T3 (es)
DO (1) DOP2015000294A (es)
EA (1) EA201501174A1 (es)
ES (1) ES2782624T3 (es)
GB (1) GB201310028D0 (es)
HR (1) HRP20200456T1 (es)
IL (1) IL242704B (es)
LT (1) LT3003401T (es)
MA (1) MA38650B1 (es)
MX (1) MX366028B (es)
MY (1) MY180717A (es)
NI (1) NI201500173A (es)
PE (1) PE20160215A1 (es)
PH (1) PH12015502715B1 (es)
PL (1) PL3003401T3 (es)
PT (1) PT3003401T (es)
RS (1) RS60091B1 (es)
SA (1) SA515370233B1 (es)
SG (1) SG11201509856RA (es)
SI (1) SI3003401T1 (es)
TN (1) TN2015000527A1 (es)
UA (1) UA120352C2 (es)
WO (1) WO2014195423A1 (es)
ZA (1) ZA201600027B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201600158D0 (en) * 2016-01-05 2016-02-17 Bayer As Purification method
GB201600161D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope purification method
CA3208778A1 (en) 2021-01-22 2022-07-28 Bayer Aktiengesellschaft Lrrc15 antibodies and conjugates thereof
NO347755B1 (en) * 2021-10-21 2024-03-18 Blue Wave Therapeutics Gmbh Peptide-coupled alginate gels comprising radionuclides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5749042A (en) * 1997-01-28 1998-05-05 Battelle Memorial Institute Bismuth generator method
GB0308731D0 (en) 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
US8481694B2 (en) * 2009-04-29 2013-07-09 Bio-Rad Laboratories, Inc. Purification of immunoconjugates
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
GB201105298D0 (en) * 2011-03-29 2011-05-11 Algeta Asa Pharmaceutical preparation

Also Published As

Publication number Publication date
RS60091B1 (sr) 2020-05-29
MX366028B (es) 2019-06-21
US20220023449A1 (en) 2022-01-27
SG11201509856RA (en) 2015-12-30
JP2016521700A (ja) 2016-07-25
MA38650B1 (fr) 2019-05-31
NI201500173A (es) 2016-01-06
CA2914278C (en) 2022-11-01
PE20160215A1 (es) 2016-05-22
ES2782624T3 (es) 2020-09-15
KR20160030893A (ko) 2016-03-21
PT3003401T (pt) 2020-04-09
ZA201600027B (en) 2018-07-25
PH12015502715A1 (en) 2016-03-28
CN105592863A (zh) 2016-05-18
AU2014276885B2 (en) 2018-12-06
NZ714737A (en) 2021-02-26
WO2014195423A1 (en) 2014-12-11
KR102321763B1 (ko) 2021-11-05
MX2015016726A (es) 2016-06-28
US20160114063A1 (en) 2016-04-28
CU20150174A7 (es) 2016-06-29
DOP2015000294A (es) 2016-03-15
AU2014276885A1 (en) 2015-12-17
CL2015003554A1 (es) 2016-07-15
LT3003401T (lt) 2020-06-25
IL242704B (en) 2020-06-30
EP3003401A1 (en) 2016-04-13
UA120352C2 (uk) 2019-11-25
EA201501174A1 (ru) 2016-10-31
CU24535B1 (es) 2021-07-02
AP2015008894A0 (en) 2015-12-31
TN2015000527A1 (en) 2017-04-06
HRP20200456T1 (hr) 2020-06-26
JP6580559B2 (ja) 2019-09-25
SA515370233B1 (ar) 2019-05-30
DK3003401T3 (da) 2020-04-06
MY180717A (en) 2020-12-07
GB201310028D0 (en) 2013-07-17
CN105592863B (zh) 2020-03-10
EP3003401B1 (en) 2020-01-15
SI3003401T1 (sl) 2020-06-30
MA38650A1 (fr) 2018-03-30
PH12015502715B1 (en) 2016-03-28
CA2914278A1 (en) 2014-12-11
PL3003401T3 (pl) 2020-07-27
BR112015030298A2 (pt) 2017-07-25

Similar Documents

Publication Publication Date Title
ECSP18053055A (es) Agonista triple de receptores de glucagón/glp-1/gip
CY1121750T1 (el) Cot διαμορφωτες και μεθοδοι χρησης αυτων
ECSP17010156A (es) Compuestos aminopirimidinilo como inhibidores jak
CR20160257A (es) Anticuerpos e inmunoconjugados anti-cd33
CL2018000088A1 (es) Métodos para fabricar un compuesto elastómero reforzado con sílice y productos que lo contienen
CL2017003205A1 (es) Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen.
DOP2015000261A (es) Compuesto peptídico como activador de los receptores del glp-1 y del gip
NI201700167A (es) Terapias combinadas para hemo malignidades con anticuerpos anti-cd38 e inhibidores de survivina
CR20150049A (es) Anticuerpos e inmunoconjugados anti-cd79b
AR115788A2 (es) Dispositivos de decodificación y codificación, y método de codificación, en un sistema de audio de canales múltiples
CL2018000087A1 (es) Métodos para fabricar un compuesto elastómero reforzado con sílice y productos que lo contienen
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
CL2018000371A1 (es) Complejos de anillos macrocíclicos de pentaaza que poseen biodisponibilidad oral.
CR20150642A (es) Preparado farmaceutico
CL2016000032A1 (es) Sistema de acoplamiento de un elemento auxiliar en una silla de ruedas
EA201890828A1 (ru) Оптимизированная таблетка с высокой дозой активного соединения, содержащая месалазин
ZA201606375B (en) Machine for generating unstructured syntax
UY36150A (es) Derivados de naftiridinadiona
CU20160069A7 (es) Sistema multiparticulado para administrar drogas
BR112017002139A2 (pt) ?método para preparar um composto?
UY35823A (es) Profármacos de antagonista de nmda
CR20140051A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
MA42889B2 (fr) Triple activateur activant le récepteur du glucagon, du glp-1 et du gip
FR3025354B1 (fr) Creation d'isotopes par reactions nucleaires en chaine
CR20150533A (es) Compuesto peptídico